Equine Arteritis Virus Is Not a Togavirus but Belongs to the Coronaviruslike Superfamily


The nucleotide sequence of the genome of equine arteritis virus (EAV) was determined from a set of overlapping cDNA clones and was found to contain eight open reading frames (ORFs). ORFs 2 through 7 are expressed from six 3'-coterminal subgenomic mRNAs, which are transcribed from the 3'-terminal quarter of the viral genome. A number of these ORFs are predicted to encode structural EAV proteins. The organization and expression of the 3' part of the EAV genome are remarkably similar to those of coronaviruses and toroviruses. The 5'-terminal three-quarters of the genome contain the putative EAV polymerase gene, which also shares a number of features with the corresponding gene of corona-and toroviruses. The gene contains two large ORFs, ORFla and ORFlb, with an overlap region of 19 nucleotides. The presence of a "shifty" heptanucleotide sequence in this region and a downstream RNA pseudoknot structure indicate that ORFlb is probably expressed by ribosomal frameshifting. The frameshift-directing potential of the ORF1a/ORF1b overlap region was demonstrated by using a reporter gene. Moreover, the predicted ORFlb product was found to contain four domains which have been identified in the same relative positions in coronavirus and torovirus ORFlb products. The sequences of the EAV and coronavirus ORFla proteins were found to be much more diverged. The EAV ORFla product contains a putative trypsinlike serine protease motif. Our data indicate that EAV, presently considered a togavirus, is evolutionarily related to viruses from the coronaviruslike superfamily. 

Equine arteritis virus (EAV) was first isolated from a fetus aborted during an endemic disease outbreak in pregnant mares (9). Serological evidence suggests that the virus is widespread in the horse population and only rarely causes disease. If it does, the clinical features are acute anorexia and fever, usually accompanied by palpebral edema, con- junctivitis, nasal catarrh, and edema of the legs, genitals, and abdomen. In infected pregnant mares, abortion is common (10,15). A carrier state exists in seropositive stallions, in which EAV is produced in semen (47). These "shedding stallions" may consequently infect brood mares by a vene- real route. Field isolates are rare and may be difficult to propagate in cell culture, and consequently the biology of EAV is poorly understood. 
EAV has been classified as a member of the togavirus family (34,53). The spherical enveloped EAV particle has a diameter of 50 to 70 nm (25). It consists of an icosahedral core structure of 35 nm (23) surrounded by an envelope carrying ringlike structures with a diameter of 12 to 15 nm (30). The viral genome is a single-stranded RNA of positive polarity with an estimated Mr of 4,000,000 (51). Four or five virion proteins have been described: a nucleocapsid (N) protein of 12 kDa, an unglycosylated 18-kDa envelope protein, a 21-kDa envelope protein, and one or two larger envelope proteins which, probably due to glycosylation, give rise to heterogeneous material of between 28 and 40 kDa (8a, 25, 54). During EAV replication, a 3'-coterminal nested set of seven virus-specific RNAs are produced, ranging in size from genome length (13 kb) to 0.8 kb (8, 48, 49). Viral subgenomic RNAs (sgRNAs) are composed of leader and body sequences which are not contiguous on the EAV genome. The sgRNAs may be produced by alternative splicing, since their leader sequence is derived from the extreme 5' end of the EAV genome (8). 
In order to study the genome organization, replication strategy, and polypeptide composition of EAV, we have determined its genomic sequence. Our data reveal an ances- tral relationship between EAV and the coronaviruses and toroviruses, two virus groups for which we recently pro- posed a superfamily status (40). Interestingly, coronaviruses and toroviruses display similar genome sizes and virion architecture which are completely different from those of the arteriviruses. 

MATERIALS AND METHODS

cDNA clones and nucleotide sequence analysis. Generation of EAV cDNA, mapping of clones, subcloning of restriction fragments in M13 vectors, and DNA sequence analysis were performed as described previously (8). 
Computer analysis of sequence data. Nucleotide sequence data were assembled and analyzed with the computer soft- ware designed by Staden (43). Amino acid sequence similarity searches were carried out with the FASTA program (31) and the NBRF protein identification resource (release 22.0). Dot matrix comparisons, sequence alignments, and polypep- tide structure analysis were carried out by using the COM- PARE, GAP, and PEPTIDE STRUCTURE options from the software provided by the Computer Genetics Group/Univer- sity of Wisconsin (version 5, 1989 [7]). Sequence alignments were optimized by visual inspection. Construction of pFSEAV and pFSEAV8. Construct pFSEAV (see Fig. 4A) was similar to vector pBSFS, which had been developed to test ribosomal frameshifting dur- ing Berne virus polymerase gene expression (40). An in- termediary construct from the pBSFS construction, named pBSMBB (40), was used to create pFSEAV. Vector pBSMBB contained a copy of the mouse hepatitis virus (MHV) A59 membrane (M) protein gene into which BglII and BamHI linkers had been inserted. Following digestion of pBSMBB with BglII and BamHI, pFSEAV was generated by cloning a 425-bp Sau3A-Sau3A fragment (nucleotide [nt] positions 5368 to 5793 in Fig. 2) from EAV clone 579 into pBSMBB. This 425-bp fragment contained the EAV poly- merase open reading frame la (ORFla)/ORF1b overlap region (see Fig. 4A). 
Construct pFSEAV8 was obtained by deleting the region between the SmaI (nt position 5512 in Fig. 2) and PvuII (nt position 5788 in Fig. 2) sites from the EAV ORFlb sequence in pFSEAV. A HindlIl site, which is present downstream of the hybrid gene in the pBS multiple cloning region, was used for this purpose (see Fig. 4A). pFSEAV was digested with PvuII and HindIlI, and the restriction fragment which con- tained the EAV ORFlb/MHV M (C terminus) junction was purified. This fragment was recloned into SmaI-and HindlIl- digested pFSEAV, resulting in a 276-bp deletion (nt posi- tions 5515 and 5790 in Fig. 2), which leaves the EAV ORFlb reading frame intact. 
The orientations of inserts and nucleotide sequences at the MHV M/EAV polymerase junctions were examined by sequence analysis. The hybrid genes in pFSEAV and pFSEAV8 were under the control of the pBS T7 promoter. 
In vivo expression of pFSEAV and pFSEAV8. pFSEAV and pFSEAV5 were expressed in vivo by transfection of HeLa cells. The HeLa cells had previously been infected with vaccinia virus recombinant vTF7-3, which contains the T7 polymerase gene under the control of a vaccinia virus promoter (11). Infections, transfections, and metabolic la- beling were performed as described previously (40). Immu- noprecipitation of expression products with antisera directed against the N and C termini of the MHV M protein were carried out as described before (40). In order to reduce aspecific precipitation, 0.2% sodium dodecyl sulfate (SDS) (instead of 0.1%) was used in immunoprecipitations with the N-terminal antiserum. 
Nucleotide sequence accession number. The sequence re- ported here has been assigned EMBL accession number X53459. 
RESULTS AND DISCUSSION Nucleotide sequence analysis of the EAV genome. The synthesis of a genomic EAV cDNA library and the mapping of clones which cover all but the 18 nucleotides at the 5' end of the EAV genome have been described recently (8). By similar methods, additional cDNA clones were obtained which allowed sequence analysis of the EAV genome on at least two independent cDNA clones (Fig. 1). However, nt 19 to 355 were present only in cDNA clone 586. This clone contained the EAV genomic leader sequence, which is adjoined to the 5' end of all EAV RNA species. Partial sequence analysis of clone 586 has been reported previously (8). 
The consensus nucleotide sequence of the EAV genome (12.7 kb) and the deduced amino acid sequences of EAV proteins are presented in Fig. 2. The primer extension experiments which were used to determine the length of the 3' 
l 61 b | M m ORFs lb 131 R RNA AAAAAA 1 E- AAAAAA 2 E-A AAAAA 3 E-AAAAAA 4 in-AAAAAA 5 EAAAAAA 6 E-AAAAAA 7 FIG. 1.
Organization of the EAV genome. The cDNA clones which were used in the sequence analysis of the EAV genome are indicated in the upper part of the figure. Dotted lines indicate the parts which were sequenced. The lower part of the figure shows the positions of the ORFs (based on the sequence) and the positions of the sgRNAs (based on RNA lengths estimated from the gel; see text). The solid box indicates the EAV leader sequence. 
EAV leader sequence (8) were repeated with an oligonucleotide which is complementary to positions 81 to 100 in the sequence presented in Fig. 2 (data not shown). The EAV leader sequence was calculated to be 207 nt long (1 nt shorter than reported previously [8]), indicating that the sequence in Fig. 2 lacks only the 18 most-5'-terminal nucleotides of the EAV genome. Experiments to obtain this sequence are in progress. 
EAV genome structure and expression. Eight open reading frames (ORFs) were identified in the EAV genome (Fig. 1 and 2). We assume that ORFla and ORFlb, which take up about 75% (9.7 kb) of the genome, are translated from the genomic RNA and encode the EAV polymerase (POL) or replicase (see below). The other six ORFs, which are par- tially overlapping, are thought to be expressed from six subgenomic mRNAs generated in EAV-infected cells. The bodies of these 3'-coterminal mRNAs are homologous to the 3' end of the genome (8). In addition, they contain a common leader sequence at their 5' end (8) (Fig. 1). We have reestimated the lengths of the EAV sgRNAs (reported earlier by van Berlo et al. [48]) on the basis of the agarose gels presented by de Vries et al. (8). Sizes of 3.2, 2.7, 2.2, 1.9, 1.2, and 0.8 kb [including a poly(A) tail] were now calculated for EAV mRNAs 2, 3, 4, 5, 6, and 7, respectively. Some characteristics of and our proposed nomenclature for the EAV RNAs and ORFs are listed in The sequence 5'-UCAAC-3' has been identified as the site where the EAV leader sequence is joined to the body of sgRNAs 6 and 7 (8). As a result, ORFs 6 and 7 are located in the "unique" 5'-terminal regions of these RNAs. The EAV genome was found to contain 18 UCAAC motifs (indicated in Fig. 2), and all ORFs (except ORFlb) are preceded by one or more of these motifs. The sizes of the bodies of EAV sgRNAs 2 through 5 closely correspond to the positions of UCAAC junction motifs and ORFs 2 through 5 on the genome (Fig. 1 and2). 
H A T F S'A T G F G G S F V R'D W S'L D L P D A C'E H G'A G L C C E V D G S T L C A E C F' GGTCACTGCCATCGTCGTCGATCTCTATCAACTACCCTTGCGACTATGGCAACCTTCTCCGCTACTGGAM66AGGGA6 G IGTTAGGGATGGTCCCTGGAMTACCCGACGCTTGTGAGCATGGCGCGGGATTGTGCTGCGAAGTGGAC6GCCCACCTTATGCGCCGA6GTGTM 46 R G C 'E G N E Q C P G L F 'M G L I K L A' S P V 'P V G H K F L' I G W 'Y R A A K V T G R Y N F L E L L Q H P A F A Q L R V V CGCGGTTG GTGGGCMTGTCCTGGCTTGTTCATGGGACTGTTAAT GGCTTCGCCAGTTCCAGTGGGACATAAGTTCCTGATTGGTTGGTATCGAGCTGCCAMGTCACCGGGCGTTACAAMCCTTGAGCTGTTGCMCACCCTGCMCGCCCAGCTGCGTGTGGTT D A R 'L A I E E A S V F I S T D H A S A' K R F 'P G A R F A L' T P -V 'Y A N A W V V' S P A 'A N S L I V T T D Q E Q D 6 F C W' GATGCTAG;6TTAGCCATTGATAGAGGCAATTM MACTGAC CACGCGTCT GCTAA GCGMMCCTGGCGCTA6 AMGCGCTGACACC GGTGTATGCTAACGCTTGGGTTGTGAGCCCGGCTGCTAACAGMTGATAGTGACCACTGACCAGACAAT6GGTTCTGCTGG L K L L P P D R R E' A G L 'R L Y Y N H Y' R E Q 'R T G i L S K' T G L 'R L W L G D L' G L G 'I N A S S G G6 L K F 'H I N R G S P' T 6MAAMTCACCT6 MCCGTGAGGCTGGMCGTTGC6TTATTACA ACCATTACGAAAGACC6GC6TGGCTGTCTACGATCGCTTATGGCTTGGAGACCTGG GTTTGGGACTGGTTGGAGGGCTGAMTTCCACATTATAGTCGCCT Q R A W H I T T R S' C K L 'K S Y Y V C D' I S E 'A D W S C L P' A G N 'Y G G Y N P P' G D G 'A C G Y R C L' A F N HN G A -T V V S' CA6CCGAGMGGCATATCACAAGACGAGCTGAAGAGCTACTACGTT1GTGACATTCTGACACTGG6TCCTGMG 1CCTGCTGGCAACTACGGCGGCTACMATCACCAGGGGAGGAGCTTGCGGTTACAGGTGCTTGGCCTTCATGAATGGCGCCACTGTTGTGTCG A G C 'S S D LW C D' D E L 'A Y R V F Q L' S P T 'F T V T I P G' G R V 'C P N A K Y A' M I C 'D K Q H W R V' K R A 'K G V a L C L' 1081 GC TTGlT6666TATAn GCTTATCGAGTC MCAATTGTCACCCA CGTTCACGGTTACCATCCCA^GGTGGGCGAGMGTCCGAATGCCAAGTACGCAATGAMGTACGCGCCGGCGC GTCAAACGT TGCMAGGGCGTCGGCCTGTGTCTC D E S C F R G I C N C Q R N S G P P P A P V S A A V L D H I L E A A T F a N V R V V T P E G Q P R P V P A P R V R P S A

GAGACG CAG CGATTMCCTATGGACCACCACCTGCACCCGTGTCAGCCGCCGT6TnAGATCKACAATGGCGCGACGMGG6CAACGTTCGCGTGGTTACACCTGM4GGCAGCCACCCMGTACUCAGCCCGCGAGTTCGTCCCAGC6CC

N S S G D V K D P A' P V P P V P K P R T K L A T P N P T Q A P I P 
A P R T R L Q G A S T Q E P L A S A G V A S D
W R V A K T V Y S S A E R F R T E L V Q R A R S V 6 D V L V Q A L P L K i P A V Q R Y T H T i K H H R S R F S W H C D V TGGCGTTGGMMACTG6TGTCGs GGGMGACAAC66TGTc6 aTGGTA6TCAACGTCTCGT GGACTTTTTc6TM cCAAGGCTACCGTCAAACCCACGTCGGTATAcA TCCTGAACTTAAGATGATGCTrCACGMcAGTTGGCACTGCGACGTG W Y P L A V I A C L L P I W P S 1 A L L L S F A I G I I P S V G N N V V L T A L L V S S A N Y V A S H D H Q C E a A A C TGGTACCCTTTGGCTGTAATCGCTTGTTGCTCCCATATGCATCTCGCMGCTACTTTCcAGCTGCCTTGGT6ATACCCA6TTGTGGGCMT6TG6TTGTT6CAGcTGCT66CTGMATCAGCTATTATGTTTGCTCAATGGACCATCAATGTGAAGGT6CGGCTTGC L A L L E E E H Y Y R A V R W R P I T 6 A L S L V L N L L G Q V G Y V A R S T F D A A Y V P C T V F D L C S F A I L Y L TTAGCCTTCGAG ACCATAAACGCGTGGM_=iGATTAA G6c6cTG6GTTGTCTCM A6TGGAGAGCTATGTAGCTCGTTCCACCTTTATGCAGCTTATGTTCC T Gc6TTcATCTTTGCAGCMGCTATTCTGTACCTC C R N R C W R C F G R C V R V G P A T H V L G S T G Q R V S K L A L I D L C D H F S K P T I D V V G N A T 6 W S G C Y T TGCGCMCGTGCGGGATCTCGGC 6T11TCAGTGCCGCCCATG CCACCGGGCAACGAGMCCA AACTGGCGCTCATTGAMGTGTGC)CCACTTCAAAGCCCACCACGATGTTTCMCA6T6CA6CTGTGGGGATGTTACACA G T A A N E H Q C A S T V *D P H S F D Q K K A 6 A T V Y L T P P V *N S G s A L Q C L N *V H W K R P G S T *V L G E Q I G GGAACCGCCCATGGAGOTcAcTcTGCTTc=6ACGGTGGAcCcTCACGT6TCGCAAAGCAuGcGzTAGcGcACTG CCcTTCAMCCTGTCAACGGGTCAGCGCTGATCTMTGCTTGGAGGACCTTGTCCAGXTTGGGACAAAG A V V T A V K S I S F S P *P C C V S T T L P T *R P G V T V V D H A L Y N H L T A S G V D P A I L R V G Q G D F L K L N P GCTGT6TGTACGGCGGTCAAGATATCTCTCGWCAM TCCC C C ACMTGCCCCACMGAMCGGTTGAMGTTGCCATGCCM ACAACCGGTTGACTGCTTCAGG6GTCGATCCCGCMATTGCGTTGTFGGCAAGTGATTTCTAAAACTTMTCCG G F R L I G a W I Y G I C Y F V L V V V S T F T C L P I K C G I G T R D P F C R R V F S V .P V T K T Q E H C H A a H C A 666,TTCc66TGATAGTGGTGAATGGGATATGTATT66TG6TTGG GGTGCAAcrMAMcTG ACCTATCMATGTW6ATTGGCACC6CGGAcCcmTTTCGMGAGAGTTM ||CTGTACCCGTCACAGMAAGAG4&CACGCCATGCTGGAATGTGTGCT S A E G I S L D S L G L T Q L Q s Y W I A A V T S G L V I L L V C H R L A I S A L D L L T L A S P L V L L V F P W A S V AGGTAGCTTTTG TTTGGTATATTACMA6TTACT66AkTCGCAGCCGT CACATCTT6AGTATC TTGTCTGCCAC CGMcTGGC CATCAGCGCCTT GGACTT GTTGACTCTAGCTTCcCcMAT | |GC | | TGTTCCCTTGGGCATCTGTG C L L L A C L A 6 A A V K I Q L I A T L F V *N L F F P Q A T L V T N G V W A C V A A L A V Y S L M G L R V K V N V P M GGG6CTM| ACTTGCT lT6AAI ITTI ITIGTGAATcCTTTCTMCAACTACTTGTCCAGGATACTGCGCGTGGCGGCMGGCCGACGcMGAGGCTTGCGATGAAAGTGAATGTGCCCATG C V T P A H F L L L A R S A G Q s R E Q N L R V S A A A P T N S L L 6 V A R D C Y V T G T T R L Y I P K E G G N V F E 6 TGTGTGACCCTGC TGGCTCGTGATTGTTATGTCCAGGCACATCGCTAATACCCAAGGAA6GGCGGATGGTGMGAAGGG L F R S P K AR G NI V G F V A G ss Y G T G S V W T RN N E V V V L T A S H V V G R A N M A T L K I G D A N L T L T F K CTAHr NVwFA6TSTC_CSVHCACICR ETCTATGANAILKACMCD A MLTLTFK K N G D F A E A V T T Q S E L P 6 N H P Q L H F A Q P T T 6 P A S W C T A T G D E E G L L S a E V C L A W T T s a D S G AAGAATGGCGACTTCGCCGAGGCAGTGACGACACAGTCCGAGCTCCCAGGCMATT6CACAGTTGATTTCGCCCAACCAACAACCGGGCCCGCTTCATGGTGCACTGCCACAGGAGATGAAGAAGGCTTGCTCAGTGGCGAGGMGTCTGGCGT66GCACTACTATGGCGACTCTGGA S A V V Q G 0 A V V G V N T G S N T s G V A Y V T T P S 6 K L L G A D T V T L S S L S K H F T G P L T S I P K D I P 0 N TCTGCA6T6GTTCAGGT6ACGCTGTGGTAGGGGXCACACACGGTTCGAACACAAGTG6TGTTGCCTACGTGACCAcCCCAAGCGGMAAMCTCCTTGGCGCCGACACCGTGACMGTCATCACTGTCAAAGCAMCACAGGcCCCMGACAATcCAACAAGGACATCCCTGACAAC I I A D V D A V P R S L A N I I 0 G L S N R E S S L S G P Q L L L I A C F H W S Y L N Q P A Y L P Y V L G F F A A N F F ATTATTGCCGATGTTGATGCTGTTCCTCGTTCTCTGGCCATGCTGATTGATGGCTTATCCAATGGGG_CTTT CTGGACCTCAGTTGTTGTTMTTGCTTGTMATGTGGTCTTATCTTAACCAACCTGCTTACTTGCCTTATGTGCTGGGCTTCTrTGCCGCTAACTTCTTC L P K S V G R P V V' T G L 'L W L C C L F T P L S M R L C L F H L V C A T V T G N V I s L W F Y I T A A G T S Y L S E M W CTGCCAMATGTGCCGCCCTGTGGTCACTGGGCTTCTATGGTTGTGCTGCClTMCACACCGCCMATGCGCTTCTTGTGTTGTTCCATCTGGCTTGCTACCGTCACG6GGMACGTGATATCTTTGTGGTTCTACATCACTGCCGCTGGCACGTCTACCTTTCTGAGATGTGG F G G Y P T N L F V P R F L V V Q F P 6 W A I 6 T V L A V C S I T M L A A A L G H T L L L 0 V F S A S G R F D R i F N N TTCGAGCTATCCCACATGTTTTTGGCACGGTTCCTAGTGTACCAGTTCCCCGGCTGGGCTATTGGCA6ATACTAGCGGTATGCAGCATCACCATGCTGGCTGCTGMCCTCGGTCACACCCTGTTACTGGATGTGTTCTCCGCCTCAGGTC6CM6AGG-ACTTTCATGATG K Y F L E G 6 V K E S V T A S V T R A Y G K P I T Q E S L T A T L *A A L i D D D F Q F L S D V L D C R A V R S A M N L C AAATACTTMTGGGGGATMGTTCACCGCCTCAGTCACCC GCGCTTATGG CAACCMATTAC MAGAATCTCACTGCAACATTAGCTGCCCTCACTGAT GATGACTTCCAATTCCTC TCTGAT GTGCTT GACT GTCGGGCC GTCCGATCGGCAATGAATCTCGGT A A L *T S F Q V A Q Y R N I L N A S L Q V D R D A A H S R R L N A K L A 0 F A V E Q E *V T A a 0 R V V V I 0D G L 0 R A GCCGCrCTCACAATCM6CAATGCCAGTATCGTAACATCCMA6TGCATM6TGCACTCACr6CTGCTU GTAGTCGCAGACTMT GGCMAACTG6TTGCGTMCGTT GACMAATAACAGCTGGAGAC CGTGTTGTGGTTATCGACGGTCT6 GACCGCATGGCT H F K 0D D L V L V P L T T K V V C G S R C T I C D V V K E E A N D T P V K P N P S R R R R K C L P K G A Q L E W 0 R H Q CACTlTCAAGAGTTTGCGTCMGACCACCA AAGGT;c AG6TAGGCGGC CAGTCCCMTGACGTC GTTW&zC AGAGACMTGACACCCCAGTTGC AAT6GCCMTCCGAGAAGCCAAG GGCCTGCCTAAA GGTGCTCAGTTGGA GTGGGACCGTCACCAG E E K R N A 6D D D0 F A V S N D V V K R V P K Y H D P S D T R G T T V K I A G T T Y Q K V V 0 Y S G N V H *Y V E H Q E D i _ _ _ _ m _ _ C M A G G A T 6 G A T C C C A G C G A C A M C G C A G G C A C G A C A G T G A M A T C G C C G G C A C T A C C T A T C A G A A A G T G G T T G A C T A T T C A G G C A A T G T G C A T T A C G T G G A G C A T C A G G A A G A T L Y 0 V V I C K C S E S K K A K A H V A H A N P V E A V N Q CTGCTAGACTACGTGCTGCAAGGVGGACAGAAGCCTAAGATCACAAACATGCTTAAA GTGGACCCCAC GGAGCTCTCCTCC AAGAAAGCAAGGCGC GTCAC GTTGCTCATCT GCTGTTG GATCTGGCT AACCCAGTTGAGGCAGTGMATCAG L N L R A P H I F P G D V G R R T F A D s K D K G F V A L H S R T N F L A A R D F L F N I K F V C D E E F T K T P K D T TTAACGAGGCCCCACTCMCCGCATGTGGGGCGTCGGA£CCmG GACTCTAGACAAGMCGGCTACAGTcCGACAATGT1TMAGCTGCCCGGGATTMAMMCATCAAAMGTGTGCGACGAAGAGTTCACAGCCAAAAA L L G V R A' c P G 'Y W F I F R R T H R S L I D A Y W D S N E C V Y A L P' T I S 'D F D V S P G' D V A 'V T G E R W D' F E S _GiI GC GTACGMATTCCGTCGTACGCAOCC66TCSCTGITGTCTCGGCGAGATGCGMACGCGCTTCCCACCATATCTGATTTTATGTGAGCCCAGGTGACGTCGCAGTGACGGGCGAGCGATGGGAmTTTTGMTC P G G R A K R L T A D 1 V H A F Q G F *H G A S Y S Y D D K V A A A V S C D P Y R s D G V L Y N T R W G N I P Y S V P T CC_ lTTClUUCGGAGCTCT6GCTTATM6TTCCTATG6ACGACnACAGGTGGCAGCTGCTGTCAGTG6TGACCCGTATCGGTCGGACGGCGTCTTGTATMACACCCGTTGG6CAACATTCCATATTCTGTCCCAACCA N A I A T A C Y R HA G C E A V T D G T N V I A T I G P F P *E Q Q P I P D I P K S V L 0 N C A D I S C D A F I A P A A E ATGCTTTGGAGCCACGCTTGTACCGTCTGATGTGAGMTAcMGACGACCACTTGACATTGGCCCTCGACAACCATACCGGACATCCCAAAGAGCGTGCTTGACAACTGCGCTGACATCAGCTGTGACGCTTCATAGCGCCCGCTcGCAGAGl T A L c C D L E K Y N L S i Q G F V L P S V F S N V R A Y L *K E E i G 0 A P P L *Y L P S T V P S K N S Q A a I N G A E F CAGCCCTGTGGAGTrAGAATACACTMACG CAGGGT MGGTGTGGTTmTC TCCATGGTGCGG6CGTACTTMGAGAACTCTGAGA CACCATCTACTTCACATGTACCATCTAMMTITCGACAM GTTMCG6CGCTGAGTTC P T K S L Q S Y C L I D 0 N V S Q S N K S N L Q T A T N A T *C K R Q Y C S K Y K I R S I L G T N N Y I G L a L R A C L S CTCACCAAAC TAll lKCTGMGAllTTGTACATGTGCAATCCATGMGMTTAC AAAMGCCACCATGGCGACTTGTAAACGGCMACGTMATACAAGTTAGGAGCATTCTACATT66 TTCAGCCTA GGTTCT6CGCTGCCTGTTTUGG 6 V T A A F Q K A 6 K D 6 P I YV L K S K F D P I P A P D K Y C IE T D L E S C D H S T P A L V R W F A l N L I F E L ~C A M C C C 6 C A T C T G G C T T U A T G G A T 6 A C C T C C C G 6 C G G T 6 C T G G T T C G C T A C T M T C A T T T T A G m U C T A G IA P E L V-H S Y NV L * C C H D L V V A C S V A F T K R G 6 L S S 0 P I T S I S N T I Y S L V L VY T Q H N L L C L FCVFPFI A FKV10CTACGT1FTGAATTGCT0TCFGVTCTVGHVTVGIGVG5A0T0TA GCVTVCICPCANACGCQTATCTHAGVCTTCCATTTC ATACCATCTATCATTGHHVTACACCCAGCACATGITICTATGTGCF E G Y F P E I A E K Y L D 6 S L E L R D N F K Y V R V Y I Y S D D V V L T T P N Q H Y A A S F D R W V P H L Q A L L G F AAGCATT6UClCCAARTTCGAMACTGTGACTGaTGGGCTTCATACGTTC6AGT6TACATCTACTCGGACGATGTGGTTCTAACCtACACCCACCACTTACGCGCACTlTGAMG6CTGGGTCCCCCACCTGUSCAGCCTGCTAGGTTTCA FIG. 2.
Nucleotide sequence analysis of the EAV genome. The first 18 nt of the genome, which remain to be determined, are indicated by N. The deduced amino acid sequences of EAV proteins are shown. Potential N-glycosylation sites in the products of ORFs 2 through 5 are indicated by triangles. Potential TCAAC (UCAAC) leader-body junction sites in the sequence are underlined (---). 
2912 OTGCCATATACGGCTCACCACCATATACACTGCAArAATTACTATTCTTGTGGGCCCCTCTCGGTMATCCTAGAGGGCMCCTCTCGTTATTGCGAGATTCGTcGTTAGATAACGGCAAGMCCTTTCTTACTATCCTATTTrCATCTTGTGGCTTGACG NUCLEOTIDE SEQUENCE OF EAV GENOME 2913 K V D P K K T V N T S S P S F L G C R F K Q V D G K AGGTTGACCCMAMAACTGTGCA CAGCTCCCCTTCCTTMGGGCTGCCGCTTCAAGCAAGTGGACGGCAAGI K D S I I C C D E D W W T D L HN R R I S G A A R T D AGGACTCCATTATCTGCTGTGATGMG6ACTGGTGGACGGACCTCCATCGACGTATCAGTGGCGCTGCGCGTACCGAC( A C G G W F C G N C V P Y H A G H C H T T S L F A N CTTGTGGAGGGTGTTCTGTGGCAATTGTGTCCCGTACCACGCGGGTCATTGTCACACMCCTCGCTCTCGCCAAZ L C H I D Y G'S K E'E L T L V V A'D G R T T S P P G TGTGCCACATTGATTACGCAGTAAAGAGAACTAACTCTGGTAGTGGCGGATGGTCGAACAATCACCGCCxG D T L K G V V V N K'A L K N A A A'S E. Y'V E G P P G ATACGCTCAAGC-GCGTGGTGGTGAATMAGCTCTGAAMACGCCGCCGCCTCTGAGTACMGTGGAAGACCTGGC L K Q A G A D P Y F V V P K Y T V L D F P R P 6 S G TCAAACAAGCGGCCCGATCCATACTTTGTGGTGCCCAA6TATACAGTTCTTGACTTTCMCGG6CCTGGCA6T66A Q C R V K C Y G D L N Q L 6 C V G P A S V P R H I H AGGTCGA6TCAAGGGTTACGGTGTAAAATCAGCTCGGGTGCGTCGGACCCGCGCTGCCACTAACCTTTGI P H T i K V V F V P'N P D F E K G V V I'T A Y H K D CACATACCKTAAA6TGGTG1TTGTGCCMATCCACTTTGAAAGGTGTATCATCACCGCCTACCACAAT V V A V T R A S Q E L Y I Y D P F D Q L S C L L K F TCTGGcCGGTTACTAGGGCGTCTCAGGAATTATACATCTACCMCCIMGATCAGCMAGCGGGTTGTTAAGTTC K E V H L L Y T H V P I K D G V I H S Y P N C 6 P A AGGAAGTCAACCTGCTGTACACACACGTCCCCATCAA66ATGGTGTMTACACATTACCCTMTTGTG1GCCCTGCC P K E L A E H W P V V S N 0 R Y P N C L Q I T L Q Q CAAAGACTCGCTGAGCATTGGCCC6TAGTGTCCAATGATAGATACCCGMTTGCTTGCAAATTACCTTACGA D G K A R A L P D S'L F S S G R F E T N'S R A F L D ACGGCAAGCGCCTGCTCIACCAIGCCTTCM TTCTCGCCGTAGTTCGAGACTAACAGCCTICCITCCA P P L L P A D A V A L V G A S L A 6 K A'A K A A C S CACCATTGCTACVCAVACGCT 6CT6TCCCTGGTTCATT 66CTG 6CT6CT V W R H A T F Y V Q E C V D A V T S A L A A V S K L TGTGGAGCGCCCMTMATGTCCAAGAGTGTTGAT GCAGTTACACCACTCCTA A A E i A L S T E P P P A 6 Y A I'V R R r I V KR L CCGCCGATGCGGCACTGTCAACTAGCCACCTGCTGGTTATGCGATCGCTGCGCGATATATGTMAGAGCTC L Q I G S V I G P V'* C Y L A S L Q D R V T R S L L Y H I G A K H P S E Y Y E A A V S I F ;TGTTTTGCTCTAGCGGTCCCCCTTATACCACATTG6T C AAAGT TCMCAUGAACTTAGCGTTTTCCATCMnA G V E F P T I E H L T S F R T K Q Y E S A V C T V C G A A P V A K S CGGAGTGGTTMMCCACCATTGAMTGTTAACATCCTTCCGCCAGATATGAGAGTGMG6TGTGCACAG = GiGCGCCC6 6CC UCACTG C G H D I H Y R S T Y C T H C E G S P K Q N V P K V P H P I L D H L CTGCGGGCACGACATCATGTACCGCTCCACTTACGACA6AMTGTGTGAGGGTTCMCAAACAGATGGTAbCCAATCCTCAaCCWCGATWTGACAMGC R I K V G H K V V A V V A D V G G H I V F G C G6P G S H I A V P L Q S G K T F H L V K D V L A V 6VG S A T L V V P T H A S H L D C I H K GTGGGAGcTnTCACCTG TCAAAAGGTACGTGG gcT6TCGGAGGCAMCMT6 T T6 C H I T V R L P Q V G T S E G E T F V D E V A Y F S P V D L A R I L T LVPATCACAGTGCGACTGCCACAGLGCG VTCGGGVCLAGACACA L R H F V S L E P L R V C N'R F G A V C D L I K G I P Y Y E P A' GCTCCGACATTTTGTCAGCCTGACCCT § A Z6CACGTC6TT R 6 L G H R T i D S I Q C C T F P V V T L R L P T P Q S L T R P R A TCGCGG TCACCGCACAA MTTCAAGCTGTACTTCCCTG CTCTTCG T K E A E A Q D L I H P P T ACCAAGAGAAGCCAGCTGTCCATG6CCCACCTAC C W E*K Q S H K I S C L P R CTGTGCIGGCAAMGCATCAAICA~AMATTcCGTGCCTCCCGAGN V C E L'.S K P C S A G Y N V 6 kGTTGGCTAGTAACCG C A VCA EISK PA SAHCINVC' CAAGCCGGGAAcIAGTMTGCCGCGCACTCC8~ATAGMTTGTTT *K F A H P H C L V V D V Y A P SF E P Y L H P I K V P A N P V S F H V A S :ATCAAAGTGMGGMCMCTTCGM CG TCCI ;TIAI L S S T E V F LC RR6VVS XTCGCTCAACAAAGITGCITTCTG&CCGAT6T61TCICI N Q R F S F kd RK KU Kd Am A C L Q I ;CATGCCACCTGGGCCAAGAMTIGCPCTI V A N L Y H Y'S 67GCACAMAA1TTT0GCTAICCACTAITTI Q S F V Q T P V MATCTG1ITTrC CGA~NCFGCCTGGGT i N K S T V CG*C ~~U GACATCFGIC1CTACAAATTAIC S T i V Q T'I C A L S C H L V E I L L 1~V S i E G L E Y Y' n8TMCMTGGGCcCTCGAATATTACA P P C. F C P I GACTTTTAC T S i W L T E N V' WCATPCT9ACTGPCTTCTAATGGGTCG S H f I F S Q Y L I D FK P C R L N' kcCGATTCAAGCTTCCAGGTATGG Q A K I S I A Y A MIF98MCTA E G E K P L F N f' W ; HFCTill ,CFTGTAAAC C I G CAAC C F FiS CGSLILP' TAc AmTTGGTrATcA6TUTGGccTGTGATGGGT6AGTGTGTcAcTGAmAmTCTATAACTAmC TTATTCTGATMGYACAW6CCTATrCTATrT Ii CAGTCT TGCAn ATTGGlCTGTrTG iG GII CII 6G C A6T nTTGTTGAT S A A V H R G V H E V R V 1 0 L F K D L Q C D N L R A K D A F P S L G Y A L S I 6 Q S R L S Y N L Q D H i L A A H R K CGGC c6Abi I j I I _ I E V N P S H I H P H P G L T P D C F D H L E S S S Y A P F I * A Y R Q A I L S Q Y P Q E L Q L E A I N C K L I A V V A P AATTATGCCTCMMTATCATGCCTATCMGGTCTACTCCTGATTGC A L Y H H Y H L A&L T G P A T H V V P T V G Q L H Y Y A S S S I F A S S V E V L A A L L F A C I P L V T R V Y I S 14 G R A Y S G P V A L L C F F L Y F C F I C G s V G S T T I C N H T T S D T S V H L F CATTGTATCATMTTACCATC T ACC AATGGGTCG 206 F T R LAN S P S R R T S S G T L P R R K I L U6 Y A A,&V T F P S H F Q R H F A A A Q D F V V H I G Y E Y A G V T N L V H L F A N L V L T F P S L V,&C S R P V H V F A TTACGCGGCTMTGTCACCTTCMGCGCrACTTCCAGCGGCACTTTGCCGCGGCGCAAGATTTrGTAGTCCCGTTATGAATATGCc666CACTATG6T AGTGCAcGTT6TGCCAACn=nCTGcTACATsTTCCGAGCTAAn6TTGCGM ;crAATGTCnTT6C & A S C V Q *V V C S H T &S T T *G L Q L S F S F V *D E D L R L H I R P *T L I C H F A L L L *V H F ; P N P R C R C S N K I Y G C I S G L L L F V C L P C C W C T F Y P C H A A E A RA TAATGCnTTMGCGTGCAAGTGGMGTAGTCATACCAACTCAACTACTGGCTTGGGTCAACTTCTTTTmCCMGTAGATGAAGATCTACGGCTCTAnTCAGGMTACT1ATTG GG TGM TGCATTaAMTGCA_ GAGGCTTT F T Y I S H G L G H V H G H E G C R H F I & V i H S A F L Y L H P T T P T A P A I T H CL L L V L A *A K N E H P A T I TTACTTACATTAGTCATGGATTGGGCCACTGCAGTCATGG TA TM CACTCTTCTGT MTCMACCAC CACTG CGG6CTATAAC I*u6CTACTATCT 94 W L Q L Q P F G Y H V A C D V I V N L E E D K R H P Y F K L L R A P A L P L C F V A I V Y V L L R L V R H A Q R C Y L * N L S N I 66CGCAGCTGCAGCCGMGGGTATCATGTGGCTGGC6PTTATTGTCAAC1 _ CTTGG_-GAGGAWTTGC6ACTCTTAC1 TMACACTGGTACTTGCACATACTAT GAT 6 V L L F L L W G A P S H A Y F S Y Y T A Q R F T D F T L C N L T D R G V I A N L L R Y D E H T A L i,&c S A S K T C W Y TGTATTGC GCI TGGGTGCGCCATCACATGCTTIACTTCTCATACTACAMCCACGUClTTCACAG CTT 6TTGTTATGCTGAC C W- 66 C T FL D E Q I I i F G TOD C DD T YiA V P V A E VL E Q A H G P Y S A L F 0D N P P F I Y Y G R E F G I'V V L D V F TTGCACATTCCTGGACAcMACAA TAG GACGA TTGAc T G6McAnTGACACC cTACGTCMAGTGCTcAGGTCCTGGAACAGCGCrATMX TAAccTGCGuGT;GTGAT TGM6oCTM ||AMACTATGGMG6TGAATTCGGCATAGnGTcTGGATGTGMAT 126 F Y P V L V L F F L S V L P Y A T L I L E N C V S I L F I I Y G I Y S G A Y L A GIf F A A ST L A H SI V V L R Q LL GTTCTAT ccGTTTTA TGTTTTTCTTATCAGTACTACTATGCTACGCTTATCTTG TGTTAT 186 W L C L A W R Y R E T L H'A S F I S A E G K V Y P V D P G L P ,V A' A V G HN R L LV P G R P T 'I D Y AV A YG cs K 'V H LV GTGGTTATGCCTGGCTTGGCG A TACGCTTACGGCCTTTAT ATC A6CTACCC66 TTGCC 246 R L C A A E V W E P * I N G A I D S F C G D G I L G E Y L D Y F I L S V P L L L L L T R Y V A S 6GL V Y V L T A L F Y S F V L A A 11881 GAGGTTGGGCGCGGTAT GGGAGCCATAGATTCATTTTGT=lilTGAGATMAGTGAGTACTATATTACAT6TCCTCCGT TM611I =I I 54 Y I W F V I V G R A F S T'A Y A F V L L'A A F L L L V N R N I V G 'M N P R L R S' I F N 'H R Q LV V A' D F V 'D T P G P V' 12061 TATA1 I iCiG iATTAGTMT6AGGATGATTG 114 P I P R S T T Q V V V R G6 G Y TA V G H K L V D G V K T I'T S A 6G R L FS K R' T A-A 'T A Y KL Q* l N A S R R S R P Q A A S F R N G R R R Q P T S Y N D L L R N F G Q R V 12241 MCATCCCMGCTCACTACTCAGGTAGTGGTTC c _ _ _ _ _ _ 37 R K P P A Q P T Q A I I A E P G D L R H D -L N Q Q E'R A T L S S N V Q R F F N G 6 H C S L T 'A D A 66 L T' Y T V 'S W VP 12421 CCCGCCCCATMC CGC 97 T K Q I Q R K V A P P A C P. 12601 TC6TAA6ACCTAG TATTCTCTCAT6 FIG. 2-Continued.
is preceded by two UCAAC motifs, but no heterogeneity in the size of RNA 7 has been detected (8). In addition, the presence of UCAAC motifs at positions which do not correspond to an sgRNA confirms the view that it is not only the primary RNA structure at this position which determines the functionality of a UCAAC motif in leader-body joining. 
On the basis of a remarkable similarity with sequences involved in the splicing of Tetrahymena pre-rRNA (8), alternative splicing has been proposed as a possible mecha- nism for the generation of EAV sgRNAs. However, in view of the similarities between the EAV and coronavirus polymerases described in this article (see below), a role for the EAV leader sequence and the conserved pregenic UCAAC motifs in a coronaviruslike transcription mechanism would not be surprising. The presence of negative-stranded sgR-NAs in infected cells, which has recently been described for coronaviruses (35,36), would be an important indication for a coronaviruslike transcription mechanism in EAV. Experiments to study the negative-stranded RNAs in EAV-in- fected cells are now in progress. Analysis of ORFs encoded by sgRNAs. EAV ORFs 2, 3, and 4 encode polypeptides with hydrophobic N and C termini and predicted sizes of 25.6, 18.0, and 17.2 kDa, respectively (Table 1). ORF5 encodes a 28.7-kDa product with a hydrophobic N terminus and an internal hydrophobic domain. The predicted products of ORFs 2 through 5 contain 1, 6, 3, and 1 potential N-glycosylation sites, respectively (Fig. 2). In view of these characteristics, each of these ORFs may encode an envelope protein in the range between 28 and 40 kDa. ORF6 encodes a polypeptide of 17.7 kDa which is predicted to be an unglycosylated triple-spanning membrane protein. The deduced ORF7 product is 110 amino acids long (12.3 kDa). This is in good agreement with the size of the product obtained after in vitro translation of the correspond- ing sgRNA and the identification of this protein as the EAV N protein (8a, 24, 50). 
Amino acid sequence comparisons between the deduced products of EAV ORFs 2 through 7 and the sequences currently available in the NBRF Protein Identification Re- source did not reveal any significant similarities with other viral or cellular proteins. The results of a further study of the EAV structural proteins will be presented elsewhere (8a). 
EAV polymerase gene resembles the polymerase gene of coronaviruses and toroviruses. By definition, the genomic RNA of a positive-stranded RNA virus encodes the viral polymerase or replicase. ORFs of 5.2 kb (ORFla) and 4.2 kb (ORFlb) were identified in the region of the EAV genome which is not transcribed into sgRNAs. These ORFs overlap over a distance of 19 nt, ORFlb being in the -1 reading frame with respect to ORFla. To exclude possible gel- reading errors, the ORFla/ORF1b overlap sequence was determined from three independent cDNA clones. 
The organization of the EAV POL gene was found to be remarkably similar to that of the POL genes of two other evolutionarily related groups of viruses which produce nested sets of subgenomic mRNAs, the coronaviruses (3,4) and the toroviruses (40). In these two virus groups, the POL gene also consists of two ORFs, which overlap over a short distance. A subgenomic mRNA from which ORFlb could be expressed is lacking in cells infected with coronaviruses (for a review, see reference 42), toroviruses (38,39), and arteri- viruses (8,48). 
Ribosomal frameshifting, resembling that in retroviruses 
UUUUAUUU 3' U Cn II C I l U G G u G- G EAV U C A U ORF 1 a/ORF 1 b C-G U overlap A-U u region C-G U A-U G C-G C-G C-G 54 C-G nt G-C 5' AGUUAAACUGAGAGC-GUCG FIG. 3.
Predicted secondary and tertiary RNA (pseudoknot) structure of the EAV ORF1a/ORF1b overlap region. The slippery sequence G UUA AAC is indicated by a dashed line. The ORFla termination codon is underlined. The SmaI site in the downstream pseudoknot domain, which was digested in the construction of pFSEAV8, is indicated by a dotted line. (26), has been found to be the ORFlb expression mechanism for the coronavirus infectious bronchitis virus (IBV [5]). A "slippery" heptanucleotide sequence (5'-UUUAAAC-3') and a downstream RNA pseudoknot (32) were shown to be essential for efficient frameshifting in the ORF1a/ORF1b overlap region (6). Sequence analysis of the POL genes of the mouse hepatitis coronavirus (MHV-A59 [4]) and the Berne torovirus (BEV [40]) revealed that this expression mechanism and the essential sequence elements in the ORF1a/ORFb overlap region have been conserved during evolution of these virus groups. 
The frameshift-directing RNA pseudoknot, consisting of a stem-loop structure base-paired to a downstream sequence element, could also be folded at the 3' side of the EAV ORF1a/ORF1b overlap region (Fig. 3). A potential slippery sequence (5'-GUUAAAC-3') was identified just upstream of the stem of the EAV hairpin and was positioned at the 5' side of the termination codon for translation of ORFla. These findings implied that ribosomal frameshifting was also the probable mechanism used to express EAV ORFlb. In addition, they were the first indications of an ancestral relation- ship between coronavirus, torovirus, and arterivirus poly- merases. 
EAV ORFla/ORFlb overlap region directs ribosomal frameshifting. To study the frameshift-directing potential of the EAV ORF1a/ORF1b overlap region, we used the expres- sion of a reporter gene similar to that used in the study of translational frameshifting in MHV-A59 (4) and BEV (40). The EAV ORF1a/ORF1b overlap region from clone 579 was cloned into a copy of the MHV-A59 26-kDa membrane protein (M) gene positioned downstream of a T7 promoter. The resulting construct, pFSEAV, consisted of the 5' por- tion of the MHV M ORF fused in-frame to the EAV ORFla/ORF1b overlap sequence, which in turn was fused in frame to the 3' portion of the MHV M ORF (Fig. 4A). Termination of translation at the ORFla termination codon should produce a 24-kDa fusion protein (Fig. 4A). Ribosomal frameshifting would lead to the synthesis of an additional fusion protein of 41 kDa. The two predicted products could be identified by immunoprecipitation with antibodies di- rected against the N-and C-terminal parts of the MHV M protein (Fig. 4A). 
Ribosomal frameshifting was studied in vivo by transfec- tion of pFSEAV into HeLa cells which had previously been infected with vaccinia virus recombinant vTF7-3. Expression of pFSEAV led to the synthesis of proteins of 24 and 41 kDa. Both products were precipitated by the antiserum directed against the N terminus of the MHV M protein (Fig. 4B). Only the 41-kDa product was precipitated when the C-terminal antiserum was used (Fig. 4B). The amount of incorporated label in both protein bands was determined by scintillation counting, resulting in an estimated frameshifting efficiency of between 15 and 20% (the 24-and 41-kDa products contained 8 and 10 methionine residues, respectively). 
The EAV slippery sequence contains a nucleotide substi- tution compared with the corresponding sequence of coro- naviruses and toroviruses (GUUAAAC instead of UUUA AAC). EAV therefore breaks the rule that slippery se- quences consist of runs of three A, U, or G residues followed by the tetranucleotide UUUA, UUUU, or AAAC (26,46). Although this may seem somewhat conflicting with the simultaneous slippage model proposed by Jacks et al. (26), there are indications that the mRNA-tRNA base-pairing requirements at the peptidyl (P) site of a frameshifting ribosome are more relaxed than those at the aminoacyl (A) site (6, 26). In fact, this nucleotide substitution may explain the lower frameshifting efficiency (in a reporter gene) of EAV than of coronaviruses and toroviruses. 
The presence of a unique SmaI restriction site within the putative downstream sequence element of the EAV RNA pseudoknot allowed the deletion of this domain from pFSEAV (Fig. 4). Construct pFSEAV5 contained a 276-bp in-frame deletion (between the SmaI and PvuII sites de- picted in Fig. 4A) in the EAV ORFlb sequence and should produce a frameshift product of about 31 kDa which should also contain the C-terminal MHV M protein sequence. However, expression of pFSEAVb yielded only the 24-kDa product which resulted from "normal" termination of ORFla translation (Fig. 4B). Even after prolonged exposure of the autoradiographs, a 31-kDa polypeptide could not be detected. This result proved that a domain more than 71 nt downstream of the stem-loop structure is essential for effi- cient frameshifting. In view of the data on retrovirus, coro- navirus, and torovirus frameshifting, this domain is likely to be the sequence 5'-CCGGGA-3' at 70 to 75 nt downstream of the hairpin; the last four nucleotides of this sequence were deleted by the digestion of the SmaI site during the construc- tion of pFSEAV5 (Fig. 3). 
The second loop (L2, according to the terminology of Pleij et al. [32]) of the pseudoknot, which connects the hairpin with the downstream sequence element, appears to be considerably larger in EAV than in other frameshift-employ- ing viruses. On the basis of the results obtained with pFSEAVB, the length of L2 in the EAV pseudoknot is assumed to be 69 nt, whereas loops 4 to 32 nt in length have been predicted for other viral frameshifting systems (6,46). It is unclear whether the length of L2 may influence the stability of the RNA pseudoknot or the frameshifting effi- ciency. 
The ORF1a/ORF1b ribosomal frameshifting mechanism and the RNA structures involved are remarkably conserved in coronaviruses (4-6), toroviruses (40), and arteriviruses (Fig. 3). Its occurrence in EAV identifies translational frame- shifting as an ancient and probably essential regulating step in POL gene expression. 
EAV ORFlb product has sequence similarity with the polymerase protein of coronaviruses and toroviruses. The conclusion that coronaviruses and toroviruses are evolutionarily related was based on the similar organization and expression of their POL genes and on the presence of four conserved domains in their predicted ORFlb products (40). Although the EAV ORFlb (4.2 kb) is considerably smaller than the corresponding ORFs of coronaviruses (8.0 kb) and toroviruses (6.9 kb), we have identified four domains in the sequence of its product which we postulate are homologous with the conserved motifs from coronavirus and torovirus ORFlb products (Fig. IBV 578 nasvviGttKfygg-16-lmGwypkCDRanPnl lR-39-G-giyvKpGGtSSGDatTayaNsvfn-58-simi lSDDgvvc-32-KcwvepdleKgp-hefcSqht-mlvevDGdpkyLpypdpsRi lgacv 836 BEV 509 ggfcl iGvsKy--g-18-vfGsDytkCDRtfPlsfR-35-G-ml lnKpGGtSSGDatTahsNtfyn-51-f lnf lSMDsf if-29-Kswst----KghieefcSah---i iktDGeyhfL--psrgRllasl 1 746 
EAV 371 gspiylGksKfdpi-6-cl5tD9esCDRstPalvR-31-GsvaftKrGGISSGDDiTsisNt7iys-38rviy90vvit-23-Kvdpk----KtvntssDSflgcrfkqvDGkcyL-aslqdvrslI 579 IBV 2274 Hi lyGevdk--pqlGG1Htvigm-38-tv1D1 1 lddf lel lr-10-SkVvtvsiDyhsinfMtwfe-dgsikTcYp-165-lalGgsfa--vkvTEts-17-fcta-vnaSSsEaFl 1i 2598 BEV 1921 HvfsGdftevgtdiGGvHhvval-29-tlvDvcanqlyekvk-8-SkVifvniDfqdvqfMvfangeddiqTfYp-136-lalGgtiv--fktTEss-17-fftagvntSSsEvFw 2209 EAV 1236 HaclGeink--stvGGsHfifsq-27-sw yapsfepyjh-4ky m_kpcr1fwrn----a-TfYv-45-.sJyaaewas pp 8-ryivkr11SStEvF1c 1413 FIG. 5. Positions (A) and aligned sequences (B) of the conserved domains in the ORFlb product of the POL genes of the coronaviruses MHV-A59 (4) and IBV-M42 (3), the torovirus BEV (40), and the arterivirus EAV. Amino acids which are identical in all four sequences are shown in capital letters. Amino acids which are identical or conserved in EAV are underlined. Domain 1, amino acids described as conserved in the majority of positive-stranded RNA viruses (33) are indicated by asterisks. Domain 2, possible conserved cysteine and histidine residues are marked by asterisks. Domain 3, amino acids conserved in "Sindbis virus-like" RNA plant viruses (group A2 [20]) are indicated by asterisks. 
Domain 1 represents the well-known polymerase or GDD motif which has been identified in the polymerases of all positive-stranded RNA viruses (for a review, see reference 33). The best match for EAV is in alignment with coronavi- ruses and toroviruses. EAV also contains a serine instead of a glycine residue in the GDD core of the motif (SDD). 
Motif 2 is rich in cysteine and histidine residues and was originally identified by Gorbalenya et al. (18) as a possible zinc-binding finger in the IBV polymerase. Although the spacing between the cysteine and histidine residues is not absolutely conserved, the EAV ORFlb product may also contain a part of this motif. Domain 3 has been postulated to represent a nucleoside triphosphate (NTP)-binding helicase which is commonly found in proteins of both viral and cellular origin (19, 22). A role for NTP-binding proteins in RNA duplex unwinding has been suggested. Recently, the plum pox potyvirus CI pro- tein, which contains the putative helicase motif, was shown to exhibit an NTP-dependent RNA duplex-unwinding activ- ity in vitro (28). The EAV helicase motif, like that of coronaviruses and toroviruses (40), is more closely related to the alphaviruslike helicase motifs than to the corresponding domains of picornaviruslike origin (20). To date, coronavi- ruses, toroviruses, and arteriviruses are the only positivestranded RNA viruses with an unsegmented genome in which the order of the polymerase and helicase domains is reversed (i.e., the helicase domain is positioned downstream of the polymerase motif). 
The fourth conserved domain is located near the C terminus of the ORFlb product (Fig. 5) and has been described The alignment of the coronavirus 3C-like sequences with 3C proteases (Fig. 10 in reference 29) was modified to optimize the alignment with the EAV sequence. (C) Alignment of the putative EAV papainlike cysteine protease with selected cellular cysteine proteases and postulated coronavirus papainlike proteases. The figure was based on the alignment presented in Fig. 12 of reference 29. Abbreviations: BVDV, bovine viral diarrhea virus; CATB, rat cathepsin B; CATH, rat cathepsin H; CATL, rat cathepsin L; CDP, chicken calcium-dependent protease; CHT, chymotrypsin; CPMV, cowpea mosaic virus; ELA, elastase; EMCV, encephalomyocarditis virus; FMDV, foot-and-mouth disease virus; HAV, hepatitis A virus; HRV14, human rhinovirus type 14; IBV, infectious bronchitis virus strain M42; MCP, mouse cysteine protease; MHV, mouse hepatitis virus strain JHM; PAP, papain; PV1, poliovirus type 1; SBMV, southern bean mosaic virus; SIN, Sindbis virus; TRP, trypsin; YFV, yellow fever virus. 
only for coronaviruses and toroviruses (40). The central part of this domain is missing in EAV. This could imply that motif 4 consists of multiple functional domains, not all of which have been conserved in the EAV polymerase. 
Analysis of the EAV ORFla sequence. Like the ORFlb product, the EAV ORFla protein (1,727 amino acids) is considerably smaller than the corresponding coronavirus polypeptide (3,951 amino acids for IBV [3], 4,488 amino acids for MHV [29]). Comparison of the EAV and corona- virus ORFla proteins did not reveal any obvious homologous domains. This is not surprising, since the ORFla product has been reported to be much more diverged than the ORFlb protein: when the ORFla-encoded amino acid sequences of the coronaviruses IBV and MHV were compared, only moderate sequence similarities were observed (29). 
The EAV ORFla product contains a number of cysteinerich motifs (amino acids 25 to 54, 243 to 356, and 632 to 657 in Fig. 2) and some very hydrophobic regions (e.g., amino acids 525 to 575 and 890 to 970 in Fig. 2). An interesting feature is the presence of a serine protease consensus sequence between amino acids 1080 and 1220 (Fig. 6A). The alignment suggests that the histidine, aspartic acid, and serine residues at amino acid positions 1103, 1129, and 1184, respectively, form the catalytic triad of a trypsinlike serine protease. In view of the large size of the predicted EAV RNA1 translation products (187 and 346 kDa), the presence of a viral protease which can process these primary transla- tion products into smaller active units would not be unex- pected. 
The relative position of the putative EAV trypsinlike protease domain in ORFla corresponds to a putative prote- ase motif in the ORFla products of IBV and MHV (18,29). However, this coronavirus domain has been proposed to be related to the picornavirus 3C-like cysteine proteases (18,29). On the basis of sequence comparison and secondary structure predictions, the trypsinlike serine proteases and the 3C-like cysteine proteases are assumed to belong to the same protease superfamily (1,16). Therefore, the putative EAV and coronavirus proteases can probably be considered related by common ancestry. Whether a more direct rela- tionship exists, i.e., a relatively recent substitution of an active-site cysteine for serine in EAV or serine for cysteine in coronaviruses, is unclear from the alignment in Fig. 6B. Such a substitution has been postulated for the putative serine protease of southern bean mosaic virus, which ap- pears to be more closely related to 3C-like cysteine prote- ases than to conventional serine proteases (16) (Fig. 6B). In addition to sequence similarities around the active-site resi- dues, there is some similarity between EAV and coronavi- ruses in the C-terminal region of the domain, which is assumed to be involved in substrate binding (1, 16) (Fig. 6B). 
On the other hand, the spacing between the motifs which form the putative EAV protease domain is similar to the spacing in alphavirus, flavivirus, and pestivirus serine pro- teases (Fig. 6A), and EAV appears to contain the catalytic aspartic acid residue which is lacking in coronaviruses (29). 
In addition to the 3C-like protease domain discussed above, possible papainlike cysteine protease motifs have been identified in the N-terminal one-third of the MHV and IBV ORFla products (29). The sequence of the EAV ORFla protein between amino acids 158 and 178 displays some sequence similarity with the region around the active-site cysteine-tryptophan dipeptide of cellular and alphavirus papainlike proteases (21,27). The EAV sequence contains several histidine residues which could fulfill the role of active-site histidine in a papainlike protease. The most convincing alignment is obtained when the histidine at position 374 is used (Fig. 6B), although a 201-residue dis- tance between the cysteine-and histidine-containing regions appears to be rather long for a papainlike protease domain. Experimental data will have to confirm the functionality and nature of both the arterivirus and the coronavirus putative proteases. 
Coronaviruslike superfamily. On the basis of computer- assisted analysis of protein sequences and in vitro transcrip- tion and translation experiments (8a), a genome organization with the general order 5'-polymerase gene-envelope protein genes-N protein gene-3' emerges for EAV. This organization is atypical of alphaviruses and rubiviruses, in which only two ORFs are present in the genome and in which the N protein gene is always present upstream of the envelope protein- encoding region (44). However, the organization of the EAV genome, its expression through the production of a 3'- coterminal nested set of mRNAs, and the translation of the second POL ORF by ribosomal frameshifting are remark- ably similar to the characteristics of coronavirus (6, 42) and torovirus (39,40) genome organization and expression. 
During the last decade, various replicase modules have been recognized among positive-stranded RNA viruses. They form the basis for superfamilies of plant and animal viruses, each displaying characteristic features. The two largest superfamilies are those of the picornaviruslike and the alphaviruslike virus groups (14,44). More recently, we proposed a coronaviruslike superfamily (40), which would comprise the coronaviruses and toroviruses and, on the basis of the data presented here, the arteriviruses. The importance of the four conserved domains in coronavirus and torovirus polymerases ( 40) is underscored by their presence in the putative polymerase of the only distantly related EAV. This is not surprising for the polymerase and helicase activities (domains 1 and 3, respectively), as both are common to the replicases of positive-stranded RNA viruses. However, the conservation, both in sequence and in relative position, of domains 2 and 4 strongly suggests that they also play an important role in the replication of coro- naviruslike viruses. This hypothesis is supported by the fact that domain 4 has recently been identified in the putative polymerase of lactate dehydrogenase-elevating virus (LDV) (lla). Although LDV has been referred to as a possible togavirus (53), its genome consists of multiple ORFs (12) and the LDV N protein gene is located at the 3' end of the genome (13). It is tempting to speculate that this domain performs a function which is specific for coronaviruslike viruses, e.g., the synthesis of multiple subgenomic mRNAs. Since the EAV genome is only 12.7 kb in size, an infectious EAV cDNA clone can be constructed more easily than a similar clone of a coronavirus or torovirus. This will enable us to test the biological functions of domain 4 (and also of domain 2) in the near future. 
Our observations may have consequences for virus clas- sification in general. On the basis of the similarities in polymerase expression and amino acid sequence, we postu- late that the polymerase genes of arteriviruses, coronaviruses, and toroviruses have descended from a common ancestor. Logically, this evolutionary relationship should be acknowledged by taxonomic position. However, nucleocapsid architecture-a classic trait for viral taxonomy, with the same ranking as the type of nucleic acid or the presence of an envelope-is icosahedral in EAV (23), helical in coronavi- ruses (for a review, see reference 37), and tubular in torovi- ruses (52). An additional difference at the structural level is the fact that the EAV envelope does not bear the elongated spikes which are present in both coronaviruses (for a review, see reference 45) and toroviruses (24, 41). The coupling of different arrays of structural genes to the same replicase has been explained by recombination of complete genes or sets of genes (modules). Together with divergence from a com- mon ancestor, modular evolution can account for the diverse composition of viral genomes (14,44,55). The joining of a coronaviruslike replicase module to a set of structural genes which confer togavirus morphology to EAV might be an- other example of modular evolution. Viral taxonomy is faced with the dilemma of designing a system which is both intellectually satisfying and practical. 

1

 1 


1 FIG. 4 .

 14 FIG. 4. Analysis of EAV ribosomal frameshifting in vivo with constructs pFSEAV and pFSEAV8. (A) Schematic representation of the pFSEAV construct. The solid box represents the T7 RNA polymerase promoter in pBS. Open boxes indicate EAV sequences; N-and C-terminal (term.) MHV M sequences are represented by differently hatched boxes. The composition of the two predicted translation products is shown. The SmaI, PvuII, and HindlIl restriction sites which were used in the generation of pFSEAV8 are indicated. (B) SDS electrophoresis of pFSEAV (center) and pFSEAVf (right) translation products immunoprecipitated by the N-terminal (aN) and C-terminal (aC) MHV M antisera. The two lanes on the left show the result of the same immunoprecipitations with an untransfected control lysate from vaccinia virus vTF7-3-infected cells. Sizes are shown in kilodaltons. 


B 1

 1 MHiV 572 gvpvviGttKfygg-16-1ulwypkCDRauPni R-39-G-cyyvKpGGtSSGDatTafaNsvfn-58-si lSDgvvc-32-KcwvetdieKgp-hefcSqht-mlvkwOdevyLpypdpsRi lgagc 830 




  VqGPPGtGKshlaig--lavyyctA-56-TinaLPelvtdi i--vvDEVsml-16-yvyiGDpaQLp-30-fLgtCyRcpkeivdtvs-72-LG1qtqTvDSaQG-19-vnRfnVaitRakkgilc 1512 IBV 1210 VqGPPGsGKshfaig--lavyfssA-56-TinaLPevscdi 1--1vDEVsml-16-vvyvGDpaQLp-29-fLakCyRcpkeivdtvs-75-LGlnvqTvDSsQG-19-inRfnValtRakrgi lv 1506 BEV 1099 VmGPPGtGKt-tfvyd---tylskA-53-ThntLPf iksavl--iaDEVs 1i-15-wi lGDpfQLs-25-yLtaCyRcppqi lsafs-64-LGdvt-TiDSsQG-19-vriviVgcsRsthlvvv 1374 EAV 799 1eGPPGsGKtfh0vkdvlavvg-sA144-Tv-rPqgtsegetfvDVayf-13-vkgy2lrQL-20-p -37-LGhr--TiDSiQG17-rp avVavtRsqe_yi 1031 HvvyGsfnq--ki iGG6Hi 1-igl-38-tviDl 1 lddfvdivk-7-SkVvnvnvDfkdfqfMlwcn-eekvuTfYp-163-lalGgsva--ikiTEfs-17-fctn-vnaSSsEgFl i 2641 


FIG. 6 .

 6 FIG.6. Comparative analysis of possible EAV protease domains. (A) Alignment of the putative EAV trypsinlike serine protease motif with cellular and alphavirus, flavivirus, and pestivirus serine proteases. Identical residues are shown in capital letters; putative catalytic residues are indicated with asterisks. The alignment was based on sequence data and comparisons presented in references 2 and 17. (B) Alignment of the putative EAV serine protease and coronavirus 3C-like cysteine protease motifs with the 3C protease sequences of selected picornaviruses and picornaviruslike viruses. The figure was based on sequence data and comparisons presented in references 1, 16, and 29. The alignment of the coronavirus 3C-like sequences with 3C proteases (Fig.10in reference 29) was modified to optimize the alignment with the EAV sequence. (C) Alignment of the putative EAV papainlike cysteine protease with selected cellular cysteine proteases and postulated coronavirus papainlike proteases. The figure was based on the alignment presented in Fig.12of reference 29. Abbreviations: BVDV, bovine viral diarrhea virus; CATB, rat cathepsin B; CATH, rat cathepsin H; CATL, rat cathepsin L; CDP, chicken calcium-dependent protease; CHT, chymotrypsin; CPMV, cowpea mosaic virus; ELA, elastase; EMCV, encephalomyocarditis virus; FMDV, foot-and-mouth disease virus; HAV, hepatitis A virus; HRV14, human rhinovirus type 14; IBV, infectious bronchitis virus strain M42; MCP, mouse cysteine protease; MHV, mouse hepatitis virus strain JHM; PAP, papain; PV1, poliovirus type 1; SBMV, southern bean mosaic virus; SIN, Sindbis virus; TRP, trypsin; YFV, yellow fever virus. 


Table

  



  1 





  . 



TABLE 1 .

 1 Characteristics of EAV RNAs and ORFs 


	RNA	Estimated size (kb)	ORF no.	Nucleotides (first-last)	No. of amino Size of encoded (kDa)
	1	13	la	226-5,406	1,727	186.9
			lb	5,406-9,749	1,448	159.0
	2	3.2	2	9,825-10,505	227	25.6
	3	2.7	3	10,307-10,795	163	18.0
	4	2.2	4	10,701-11,156	152	17.2
	5	1.9	5	11,147-11,911	255	28.7
	6	1.2	6	11,902-12,387	162	17.7
	7	0.8	7	12,314-12,643	110	12.3

ACKNOWLEDGMENTS

We thank Peter Bredenbeek, Raoul de Groot, and Rend Rijnbrand for helpful discussions and assistance.E.C. was the recipient of a postdoctoral EMBO fellowship (ALTF 131-1988).Part of this work was supported by a research grant from Duphar BV, Weesp, The Netherlands.
Johan A Den Boon, Eric J Snijder, Ewan D Chirnside, Antoine A F De Vries, Marian C Horzinek, Willy J M Spaan'
Equine Arteritis Virus Is Not a Togavirus but Belongs to the Coronaviruslike Superfamily